MTDH Antikörper (AA 101-270)

Produktnummer ABIN3031760

Der Kaninchen Polyklonal anti-MTDH Antikörper wird verwendet zum Nachweis von MTDH in Proben von Human, Maus und Ratte. Er wurde validiert für WB, ICC und IHC (p).

Kurzübersicht für MTDH Antikörper (AA 101-270) (ABIN3031760)

Target: MTDH (Metadherin (MTDH))

Reaktivität: Human, Maus, Ratte

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser MTDH Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunocytochemistry (ICC), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Produktdetails anti-MTDH Antikörper

Bindungsspezifität: AA 101-270

Verwendungszweck: LYRIC Antibody / Metadherin / AEG-1

Aufreinigung: Antigen affinity

Immunogen: Human partial recombinant protein (AA 101-270) was used as the immunogen for this LYRIC antibody.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: The stated application concentrations are suggested starting amounts. Titration of the LYRIC antibody may be required due to differences in protocols and secondary/substrate sensitivity.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Buffer: 0.5 mg/mL if reconstituted with 0.2 mL sterile DI water

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: After reconstitution, the LYRIC antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.

Details zu MTDH

Target: MTDH (Metadherin (MTDH))

Andere Bezeichnung: LYRIC

Hintergrund: MTDH (Metadherin), also known as LYRIC or astrocyte elevated gene-1 protein (AEG-1), is a protein that in humans is encoded by the MTDH gene. It is involved in HIF-1 alpha mediated angiogenesis, interacts with SND1 and is involved in RNA-induced silencing complex (RISC), and plays a very important role in RISC and miRNA functions. LYRIC induces an oncogene called Late SV40 factor (LSF/TFCP2) which is involved in thymidylate synthase (TS) induction and DNA biosynthesis synthesis. Late SV40 factor enhances angiogenesis by transcriptionally up-regulating matrix metalloproteinase-9 (MMP9). LYRIC acts as an oncogene in melanoma, malignant glioma, breast cancer and hepatocellular carcinoma. It is highly expressed in these cancers and helps in progression and development of these cancers. It is induced by c-Myc oncogene and plays very important role in anchorage independent growth of cancer cells.

Pathways: Cellular Response to Molecule of Bacterial Origin, Cell-Cell Junction Organization